AEROVATE THERAPEUTICS INC (AVTE)
US0080641071 - Common Stock
AVTE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTE as it has an excellent financial health rating, but there are worries on the profitability. AVTE does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year AVTE has reported negative net income.
In the past year AVTE has reported a negative cash flow from operations.
AVTE had negative earnings in each of the past 5 years.
AVTE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AVTE (-93.02%) is worse than 73.84% of its industry peers.
Looking at the Return On Equity, with a value of -105.12%, AVTE is in line with its industry, outperforming 45.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93.02% | ||
| ROE | -105.12% | ||
| ROIC | N/A |
ROA(3y)-36.82%
ROA(5y)-82.65%
ROE(3y)-41%
ROE(5y)-258.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AVTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, AVTE has more shares outstanding
AVTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AVTE has an Altman-Z score of -1.37. This is a bad value and indicates that AVTE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.37, AVTE is in line with its industry, outperforming 56.41% of the companies in the same industry.
There is no outstanding debt for AVTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.37 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 8.78 indicates that AVTE has no problem at all paying its short term obligations.
AVTE's Current ratio of 8.78 is fine compared to the rest of the industry. AVTE outperforms 75.80% of its industry peers.
A Quick Ratio of 8.78 indicates that AVTE has no problem at all paying its short term obligations.
AVTE has a Quick ratio of 8.78. This is in the better half of the industry: AVTE outperforms 76.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.78 | ||
| Quick Ratio | 8.78 |
3. Growth
3.1 Past
The earnings per share for AVTE have decreased by -8.73% in the last year.
EPS 1Y (TTM)-8.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -4.03% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.85%
EPS Next 2Y32.52%
EPS Next 3Y14.4%
EPS Next 5Y-4.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AVTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AVTE's earnings are expected to grow with 14.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.52%
EPS Next 3Y14.4%
5. Dividend
5.1 Amount
No dividends for AVTE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AEROVATE THERAPEUTICS INC
NASDAQ:AVTE (12/26/2024, 8:00:01 PM)
After market: 2.63 0 (0%)2.63
+0.03 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.08%
Inst Owner Change0.41%
Ins Owners0.08%
Ins Owner Change0.14%
Market Cap75.93M
Analysts48.89
Price Target2.38 (-9.51%)
Short Float %6.21%
Short Ratio1.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.59%
Min EPS beat(2)-2.57%
Max EPS beat(2)5.75%
EPS beat(4)1
Avg EPS beat(4)-1.43%
Min EPS beat(4)-6.37%
Max EPS beat(4)5.75%
EPS beat(8)2
Avg EPS beat(8)-2.46%
EPS beat(12)2
Avg EPS beat(12)-8.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)51.16%
EPS NY rev (1m)5.57%
EPS NY rev (3m)5.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.94 | ||
| P/tB | 0.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.99
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS2.79
TBVpS2.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93.02% | ||
| ROE | -105.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.82%
ROA(5y)-82.65%
ROE(3y)-41%
ROE(5y)-258.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.78 | ||
| Quick Ratio | 8.78 | ||
| Altman-Z | -1.37 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)444.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.13%
EPS Next Y6.85%
EPS Next 2Y32.52%
EPS Next 3Y14.4%
EPS Next 5Y-4.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.66%
OCF growth 3YN/A
OCF growth 5YN/A